OCM
IMNM icon

Ovata Capital Management’s Immunome IMNM Stock Holding History

Ovata Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$494K – 43
2024
Q1 		$494K Buy
+20,000
New +$406K 0.26% 32

Other funds holding IMNM

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ovata Capital Management's IMNM Position: Q2 2024 in Review

Ovata Capital Management sold out of Immunome (IMNM) in Q2 2024, closing a stake of 20,000 shares — an estimated $494K sold.

Ovata Capital Management first reported a position in IMNM in Q1 2024 and held it in 1 quarter. The position peaked at $494K in Q1 2024. 113 funds tracked by Wall St. Rank hold IMNM as of Q2 2024.

  • Ovata Capital Management reported no remaining Immunome position as of Q2 2024 after selling out during the quarter.
  • Ovata Capital Management sold 20,000 Immunome shares in Q2 2024, an estimated $494K.
  • Ovata Capital Management first reported a position in Immunome in Q1 2024 and held it in 1 quarter.
  • Ovata Capital Management's Immunome position peaked at $494K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Immunome as of Q2 2024.

Based on Ovata Capital Management's 13F filing for Q2 2024, filed 5 Aug 2024.